Velgia® Ivf is a new wave in the treatment of obesity

July 22, Moscow

A leading innovative Biopharmaceutical Company PROMOMED announces the launch of sales of a new generation domestic drug for the treatment of overweight and obesity Velgia® Eco (active ingredient semaglutide) in disposable injectors. The drug is already available on online pharmacy resources and in pharmacy chains across the country. The key difference of the new product is the complete absence of preservatives in the composition, which brings therapy to a new level of safety.

Velgia® Eco retains all the therapeutic benefits of semaglutide obtained by solid-phase synthesis. The absence of phenol and benzyl alcohol in the composition of the drug, which can accumulate in the body, reduces the risk of adverse reactions in sensitive patients and patients with concomitant liver and kidney diseases. Disposable injectors ensure the simplicity and precision of hygienic and painless injection. The automatic injection mechanism helps to smooth out the fear of injection due to the hidden process of piercing the skin.

Velgia® Eco PROMOMED is produced at its own facilities from the substance to the finished dosage form. The range of the traditional five dosages (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) remains the same as in the classic version of the drug. Each package is designed for a monthly course of use.

Information on the approval of the maximum selling prices for the drug Velgia® Ivf (included in the list of vital and essential medicines)

Velgia® Ivf 0.25 mg – 4,279.55 rub.
Velgia® Ivf 0.5 mg – 4,279.55 rub.
Velgia® Ivf 1 mg – 4,279.55 rubles.
Velgia® Ivf 1,7 mg – 7,275.24 rubles.
Velgia® Ivf 2.4 mg – 10,270.92 rubles.